Researchers sought to determine whether elranatamab would lead to durable responses in patients with relapsed or refractory multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback